文献速递艾滋病与性传播感染病毒性肝炎

新生儿HBV疫苗时代出生与HIV/HBV共感染者接受含替诺福韦ART后HBsAg清除的关系

Birth in the neonatal HBV vaccination era and hepatitis B surface antigen seroclearance in people with HIV and HBV coinfection on tenofovir-containing antiretroviral therapy.
PubMed 文献 · Clin Infect Dis · 2026-07-11

多因素分析显示,在新生儿乙肝疫苗普及时代(1986年7月后)出生、基线HBsAg≤250 IU/mL及基线ALT较高是HBsAg清除的独立预测因素。

要点

  • 含替诺福韦ART长期治疗下HBsAg清除率仍低,年发生率0.97/100人年。
  • 1986年7月后出生者HBsAg清除可能性显著更高(aHR 13.56)。
  • 基线HBsAg≤250 IU/mL者清除可能性更高(aHR 7.36)。

核心结论

  • 尽管长期使用含替诺福韦ART,HIV/HBV共感染者HBsAg清除仍不常见,年发生率为0.97/100人年。
  • 新生儿HBV疫苗时代出生和较低基线HBsAg水平是HBsAg清除的独立预测因素。

研究设计与样本

  • 共415人,总随访3600人年,中位随访9.4年,采用Cox比例风险模型分析HBsAg清除相关因素。

主要发现

  • 415人中35人(8.4%)实现HBsAg清除,其中37.1%(13/35)在清除时抗-HBs阳性。
  • 多因素分析显示,1986年7月后出生(aHR 13.56,95%CI 6.08-30.28,P<0.001)、基线HBsAg≤250 IU/mL(aHR 7.36,95%CI 3.29-16.50,P<0.001)及基线ALT每升高1 U/L(aHR 1.00,95%CI 1.00-1.01,P<0.001)与HBsAg清除独立相关。
  • 实现HBsAg清除者中无人发生血清学逆转、肝硬化或肝细胞癌;未清除者中分别有6.6%和2.1%发生肝硬化和肝细胞癌。

临床怎么用

  • 对HIV/HBV共感染者启动含替诺福韦ART后,应长期监测HBsAg,尤其关注1986年7月后出生及基线HBsAg≤250 IU/mL者。
  • HBsAg清除后仍需监测肝硬化和肝细胞癌风险,未清除者风险更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of long-term tenofovir-containing antiretroviral therapy (ART) on hepatitis B surface antigen (HBsAg) seroclearance in people with HIV (PWH) and HBV coinfection remains under-defined, particularly in HBV-hyperendemic regions with universal vaccination programs. METHODS: HBsAg-positive PWH receiving tenofovir-containing ART between 2011 and 2023 were followed until December, 2025. Demographics, HBV serologic markers, plasma HBV DNA, and liver fibrosis stage were collected. Cox proportional hazards models were used to identify factors associated with HBsAg seroclearance. Clinical and hepatic outcomes were compared by seroclearance status. RESULTS: After a median follow-up of 9.4 years, 35 (8.4%) of 415 PWH achieved HBsAg seroclearance during a total of 3,600 person-years of tenofovir-containing ART, corresponding to an incidence rate of 0.97 per 100 person-years. Among them, 37.1% (13/35) tested positive for anti-HBs at the time of seroclearance. In multivariable analysis, birth in universal neonatal HBV vaccination era (after July 1986) (adjusted hazard ratio [aHR] 13.56, 95% confidence interval [CI] 6.08-30.28, P<0.001), baseline HBsAg ≤250 IU/mL (aHR 7.36, 95% CI 3.29-16.50, P<0.001), and higher baseline ALT level (aHR 1.00 per 1-U/L increase, 95% CI 1.00-1.01, P<0.001) were independently associated with HBsAg seroclearance. None of PWH who achieved HBsAg seroclearance developed seroreversion, cirrhosis, or hepatocellular carcinoma, whereas 6.6% and 2.1% of PWH without seroclearance developed cirrhosis and hepatocellular carcinoma, respectively. CONCLUSIONS: Despite long-term tenofovir-containing ART, HBsAg seroclearance was uncommon (0.97% annually) among PWH with HBV coinfection. Birth in the neonatal HBV vaccination era and lower baseline HBsAg level were two independent predictors of HBsAg seroclearance.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Huang YS, Sun HY, Lin KY, et al. Birth in the neonatal HBV vaccination era and hepatitis B surface antigen seroclearance in people with HIV and HBV coinfection on tenofovir-containing antiretroviral therapy. Clin Infect Dis. 2026. PMID: 42435456. doi:10.1093/cid/ciag429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。